

June 9th, 2025

Dear Valued Baxter Customer,

Baxter Healthcare launched or is expecting to launch in Q2 2025 two new NDCs for DOXIL (doxorubicin hydrochloride liposome injection).

- 20 mg / 10 mL (2 mg / mL) single-dose vial: 00338-9667-01 to eventually replace 00338-0063-01
- 50 mg / 25 mL (2 mg / mL) single-dose vial: 00338-9665-01 to eventually replace 00338-0067-01

Because the new NDCs are the same product (drug, dose, formulation, or volume) with the same 340B price as the corresponding NDCs, **Baxter Healthcare** believes that a covered entity utilizing a 340B inventory replenishment model may count accumulations of the old NDCs toward replenishment of equal quantities of the corresponding new NDCs (see table below).

	SKU	NDC	Name
NEW	LD0020B	00338-0063-01	DOXIL (doxorubicin hydrochloride liposome injection) 20 mg / 10 mL (2 mg / mL) single-dose vial
	2321B0132	00338-9667-01	DOXIL (doxorubicin hydrochloride liposome injection) 20 mg / 10 mL (2 mg / mL) single-dose vial
NEW	LD0050B	00338-0067-01	DOXIL (doxorubicin hydrochloride liposome injection) 50 mg / 25 mL (2 mg / mL) single-dose vial
	2321B0332	00338-9665-01	DOXIL (doxorubicin hydrochloride liposome injection) 50 mg / 25 mL (2 mg / mL) single-dose vial

If you have any questions regarding this notice, please contact your Baxter representative or the Center for Service at 1-888-229-0001.

Sincerely,



Joanne Manidis
VP of Pharmaceuticals
Pharmaceuticals by Baxter